HEMATOLOGY / BASIC RESEARCH
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Long non-coding RNA (lncRNA) nuclear enriched abundant transcript 1 (NEAT1) is confirmed to be involved in regulation of the multiple myeloma (MM) process. However, its underlying molecular mechanism deserves further investigation.

Material and methods:
Quantitative real-time PCR was used to examine NEAT1, microRNA (miR)-133a and actin-related protein 2/3 complex subunit 5 (ARPC5) expression. Cell proliferation and apoptosis were evaluated by cell counting kit 8 assay, soft-agar colony formation assay and flow cytometry. Dual-luciferase reporter assay was used to confirm the interaction between miR-133a and NEAT1 or ARPC5. The localization of NEAT1 and miR-133a in MM cells was determined by fluorescent in situ hybridization assay. In addition, animal experiments were conducted to explore the effect of NEAT1 knockdown on MM tumor growth in vivo.

Results:
NEAT1 had increased expression in MM patients and cells. NEAT1 knockdown could repress MM cell proliferation and enhance apoptosis. NEAT1 could sponge miR-133a, and miR-133a could target ARPC5. MiR-133a was lowly expressed and ARPC5 was highly expressed in MM patients. MiR-133a inhibitor could abolish the suppressive effect of NEAT1 knockdown on MM cell growth, and these effects also could be reversed by ARPC5 silencing.

Conclusions:
Animal experiments showed that NEAT1 downregulation reduced MM tumor growth by regulating miR-133a/ARPC5 axis. NEAT1 facilitated MM progression through the regulation of miR-133a/ARPC5, which provided new evidence that NEAT1 was a potential therapeutic target for MM.
REFERENCES (33)
1.
Medical Masterclass Contributors; Firth J. Haematology: multiple myeloma. Clin Med (Lond) 2019; 19: 58-60.
 
2.
Diaz-delCastillo M, Chantry AD, Lawson MA, Heegaard AM. Multiple myeloma-a painful disease of the bone marrow. Semin Cell Dev Biol 2021; 112: 49-58.
 
3.
Rene CG, Achiam MP, Salomo M, Penninga L. Extramedullary relapse in a patient with multiple myeloma: a rare cause of gastrointestinal perforation and massive bleeding. BMJ Case Rep 2021; 14: e243663.
 
4.
Gonsalves WI, Buadi FK, Ailawadhi S, et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant 2019; 54: 353-67.
 
5.
Waszczuk-Gajda A, Szafraniec-Buryło S, Kraj L, et al. Epidemiology of multiple myeloma in Poland in the years 2008-2017. Arch Med Sci 2023; 19: 645-50.
 
6.
Chen X, Sun Y, Cai R, et al. Long noncoding RNA: multiple players in gene expression. BMB Rep 2018; 51: 280-9.
 
7.
Zhang ZS, Wang J, Zhu BQ, Ge L. Long noncoding RNA UCA1 promotes multiple myeloma cell growth by targeting TGF-. Eur Rev Med Pharmacol Sci 2020; 24: 12623.
 
8.
Liu Z, Gao H, Peng Q, Yang Y. Long noncoding RNA LUCAT1 promotes multiple myeloma cell growth by regulating the TGF- signaling pathway. Technol Cancer Res Treat 2020; 19: 1533033820945770.
 
9.
Han C, Yang Y, Guo L, et al. The expression of long non-coding RNA HOTAIR in advanced hepatocellular carcinoma and its prognostic correlation with sunitinib therapy. Arch Med Sci 2022; 18: 71-8.
 
10.
Shen Q, Jiang Q, Cong Z, et al. Knockdown of lncRNA AL928768.3 inhibits multiple myeloma cell proliferation by inducing cell cycle arrest in G0/G1 phase. Ann Transl Med 2022; 10: 172.
 
11.
Chu M, Fan Y, Wu L, et al. Knockdown of lncRNA BDNF-AS inhibited the progression of multiple myeloma by targeting the miR-125a/b-5p-BCL2 axis. Immun Ageing 2022; 19: 3.
 
12.
Ghafouri-Fard S, Taheri M. Nuclear enriched abundant transcript 1 (NEAT1): a long non-coding RNA with diverse functions in tumorigenesis. Biomed Pharmacother 2019; 111: 51-9.
 
13.
Xie Y, Zheng ZW, he HT, Chang ZB. LncRNA NEAT1 induces autophagy through the miR-128-3p/ADAM28 axis to suppress apoptosis of nonsmall-cell lung cancer. Kaohsiung J Med Sci 2022; 38: 933-49.
 
14.
Che F, Ye X, Wang Y, et al. Lnc NEAT1/miR-29b-3p/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells. Eur J Pharmacol 2021; 891: 173752.
 
15.
Wu Y, Wang H. LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway. J Biochem Mol Toxicol 2018; 32(1). doi: 10.1002/jbt.22008.
 
16.
Cheng Y, Su Y, Wang S, et al. Identification of circRNA-lncRNA-miRNA-mRNA competitive endogenous RNA network as novel prognostic markers for acute myeloid leukemia. Genes (Basel) 2020; 11: 868.
 
17.
Lou C, Li T. Long non-coding RNA SENCR alleviates endothelial-to-mesenchymal transition via targeting miR-126a. Arch Med Sci 2023; 19: 180-8.
 
18.
Jin Z, Liu B, Lin B, et al. The novel lncRNA RP9P promotes colorectal cancer progression by modulating miR-133a-3p/FOXQ1 axis. Front Oncol 2022; 12: 843064.
 
19.
Wang X, Zhu L, Lin X, et al. MiR-133a-3p inhibits the malignant progression of oesophageal cancer by targeting CDCA8. J Biochem 2022; 170: 689-98.
 
20.
von Loeffelholz O, Purkiss A, Cao L, et al. Cryo-EM of human Arp2/3 complexes provides structural insights into actin nucleation modulation by ARPC5 isoforms. Biol Open 2020; 9: bio054304.
 
21.
Xiong T, Luo Z. The expression of actin-related protein 2/3 complex subunit 5 (ARPC5) expression in multiple myeloma and its prognostic significance. Med Sci Monit 2018; 24: 6340-8.
 
22.
Wu H, Dong D, Wang J, et al. LncRNA NEAT1 promotes the malignant progression of colorectal cancer by targeting ZEB1 via miR-448. Technol Cancer Res Treat 2022; 21: 15330338221085348.
 
23.
Liao G, Huang Z, Gan T, et al. Long non-coding RNA nuclear enriched abundant transcript 1 (NEAT1) modulates inhibitor of DNA binding 1 (ID1) to facilitate papillary thyroid carcinoma development by sponging microRNA-524-5p. Bioengineered 2022; 13: 13201-12.
 
24.
Xu H, Li J, Zhou ZG. NEAT1 promotes cell proliferation in multiple myeloma by activating PI3K/AKT pathway. Eur Rev Med Pharmacol Sci 2018; 22: 6403-11.
 
25.
Gao Y, Fang P, li WJ, et al. LncRNA NEAT1 sponges miR-214 to regulate M2 macrophage polarization by regulation of B7-H3 in multiple myeloma. Mol Immunol 2020; 117: 20-8.
 
26.
Yu H, Peng S, Chen X, et al. Long non-coding RNA NEAT1 serves as a novel biomarker for treatment response and survival profiles via microRNA-125a in multiple myeloma. J Clin Lab Anal 2020; 34: e23399.
 
27.
Geng W, Guo X, Zhang L, et al. Resveratrol inhibits proliferation, migration and invasion of multiple myeloma cells via NEAT1-mediated Wnt/-catenin signaling pathway. Biomed Pharmacother 2018; 107: 484-94.
 
28.
Liu W, Shi X, Wang B. microRNA-133a exerts tumor suppressive role in oral squamous cell carcinoma through the Notch signaling pathway via downregulation of CTBP2. Cancer Gene Ther 2022; 29: 62-72.
 
29.
Kong B, Zhao S, Kang X, Wang B. MicroRNA-133a-3p inhibits cell proliferation, migration and invasion in colorectal cancer by targeting AQP1. Oncol Lett 2021; 22: 649.
 
30.
Xu Y, Zhang L, Xia L, Zhu X. MicroRNA-133a-3p suppresses malignant behavior of non-small cell lung cancer cells by negatively regulating ERBB2. Oncol Lett 2021; 21: 457.
 
31.
Huang S, Li D, Zhuang LL, et al. Identification of Arp2/3 Complex subunits as prognostic biomarkers for hepatocellular carcinoma. Front Mol Biosci 2021; 8: 690151.
 
32.
Liu C, Liu R, Zhang D, et al. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes. Nat Commun 2017; 8: 14270.
 
33.
Kinoshita T, Nohata N, Watanabe-Takano H, et al. Actin-related protein 2/3 complex subunit 5 (ARPC5) contributes to cell migration and invasion and is directly regulated by tumor-suppressive microRNA-133a in head and neck squamous cell carcinoma. Int J Oncol 2012; 40: 1770-8.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top